Medallion Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Medallion Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72K	Hold	12	–	–	﹤0.01%	938
2026 Q1	$2.07K	Hold	12	–	–	﹤0.01%	993
2025 Q4	$2.39K	Hold	12	–	–	﹤0.01%	970
2025 Q3	$1.88K	Hold	12	–	–	﹤0.01%	988
2025 Q2	$1.85K	Hold	12	–	–	﹤0.01%	965
2025 Q1	$1.75K	Hold	12	–	–	﹤0.01%	938
2024 Q4	$2.21K	Buy	+12	New	+$2.31K	﹤0.01%	847

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Medallion Wealth Advisors's CRL Position: Q2 2026 in Review

Medallion Wealth Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 12 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Medallion Wealth Advisors first reported a position in CRL in Q4 2024 and has held it in 7 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Medallion Wealth Advisors held 12 shares of Charles River Laboratories worth $2.72K as of Q2 2026.
Medallion Wealth Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #938 holding.
Medallion Wealth Advisors first reported a position in Charles River Laboratories in Q4 2024 and has held it in 7 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.